Functional neuroimaging and neurophysiological patterns during Zolpidem-induced behavioral improvement in akinetic mutism: a pilot study

Functional neuroimaging and neurophysiological patterns during Zolpidem-induced behavioral improvement in akinetic mutism: a pilot study - Zolpidem in akinetic mutism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47472

Enrollment

Registered

2018-04-06

Start date

2017-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NVT

Interventions

Akinetic mutism

fMRI

Zolpidem

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Diagnosis of AM, caused by non-progressive neurological injury * Consistent temporarily restored speech and limb movement following administration of 10 mg Zolpidem

Exclusion criteria

Exclusion criteria: * Ongoing neurodegenerative disease * Standard MRI scan exclusion criteria (i.e. pacemaker and other metallic foreign bodies contraindicated for MRI) * Motor agitation interfering with MRI, EEG or MEG * Anatomical deformities that prevent the subject from undergoing MEG registration in supine position (i.e. thoracic kyphosis)

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study is functional change as measured by neuroimaging (structural MRI and fMRI), electrophysiology (EEG), and magneto-encefalography (MEG) before and after administration of Zolpidem.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)